达沙替尼诱导 1 例难治性幼年黄色肉芽肿患儿产生戏剧性反应，该患儿存在新型 MRC1-PDGFRB 融合。
Dasatinib induces a dramatic response in a child with refractory juvenile xanthogranuloma with a novel MRC1-PDGFRB fusion.
机构信息
Department of Pediatric Oncology, Children's Cancer Hospital-Egypt (57357), Cairo, Egypt.
Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN.
出版信息
Blood Adv. 2020 Jul 14;4(13):2991-2995. doi: 10.1182/bloodadvances.2020001890.
Abstract
Juvenile xanthogranuloma (JXG) usually presents with lesions isolated to the skin; however, aggressive, disseminated forms also occur. Identification of a novel fusion in a child with JXG guided targeted therapy with dasatinib, leading to a dramatic response.
摘要
幼年黄色肉芽肿（JXG）通常表现为孤立于皮肤的病变；然而，也存在侵袭性、播散性的形式。在一名患有 JXG 的儿童中发现了一种新型融合，指导了达沙替尼的靶向治疗，从而产生了显著的反应。
相似文献
1
Dasatinib induces a dramatic response in a child with refractory juvenile xanthogranuloma with a novel MRC1-PDGFRB fusion.达沙替尼诱导 1 例难治性幼年黄色肉芽肿患儿产生戏剧性反应，该患儿存在新型 MRC1-PDGFRB 融合。
Blood Adv. 2020 Jul 14;4(13):2991-2995. doi: 10.1182/bloodadvances.2020001890.
2
Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib.在一名携带DEK-NUP214融合基因的急性髓系白血病患者中鉴定出一种新型融合基因TBL1XR1-PDGFRB及其对达沙替尼的临床反应。
Leuk Lymphoma. 2017 Dec;58(12):2969-2972. doi: 10.1080/10428194.2017.1318437. Epub 2017 May 16.
3
Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report.伴有变异型ATF7IP/PDGFRB融合且对酪氨酸激酶抑制剂治疗反应良好的急性淋巴细胞白血病患者：一例报告
Am J Case Rep. 2017 Nov 14;18:1204-1208. doi: 10.12659/ajcr.906300.
4
The T681I mutation is highly resistant to imatinib and dasatinib and detectable in clinical samples prior to treatment.T681I突变对伊马替尼和达沙替尼具有高度抗性，且在治疗前的临床样本中可检测到。
Haematologica. 2021 Aug 1;106(8):2242-2245. doi: 10.3324/haematol.2020.261354.
5
Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome.达沙替尼治疗 Penttinen 综合征成人患者的临床和分子反应。
Am J Med Genet A. 2022 Apr;188(4):1233-1238. doi: 10.1002/ajmg.a.62603. Epub 2021 Dec 11.
6
TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation.酪氨酸激酶抑制剂达沙替尼单药治疗一例携带ATF7IP/PDGFRB易位的Ph样急性淋巴细胞白血病患者。
Pediatr Blood Cancer. 2015 Jun;62(6):1058-60. doi: 10.1002/pbc.25327. Epub 2014 Nov 14.
7
[An ocular variant of juvenile xanthogranuloma].[青少年黄色肉芽肿的眼部变体]
Ned Tijdschr Geneeskd. 2014;158:A7889.
8
HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2).HCMOGT-1是一种在伴有t(5;17)(q33;p11.2)的青少年粒单核细胞白血病中与PDGFRB形成的新型融合伴侣。
Cancer Res. 2004 Apr 15;64(8):2649-51. doi: 10.1158/0008-5472.can-03-4026.
9
Corneoscleral xanthogranuloma treated with chemotherapy: The room for nonsurgical management.化疗治疗角膜巩膜黄色瘤：非手术治疗的空间
Eur J Ophthalmol. 2020 Mar;30(2):NP23-NP26. doi: 10.1177/1120672119832187. Epub 2019 Feb 27.
10
Refractory juvenile xanthogranuloma of the mastoid bone responsive to trametinib.对曲美替尼有反应的乳突骨难治性幼年黄色肉芽肿
Pediatr Blood Cancer. 2024 Oct;71(10):e31211. doi: 10.1002/pbc.31211. Epub 2024 Jul 18.
引用本文的文献
1
Updates on Langerhans cell histiocytosis and other histiocytosis in children: invited review-challenges and novelties in paediatric tumours.儿童朗格汉斯细胞组织细胞增多症及其他组织细胞增多症的最新进展：特邀综述——儿科肿瘤的挑战与新进展
Virchows Arch. 2025 Jan;486(1):189-204. doi: 10.1007/s00428-024-04018-w. Epub 2025 Jan 11.
2
Promoter swapping of truncated PDGFRB drives Ph-like acute lymphoblastic leukemia.截短型血小板衍生生长因子受体β（PDGFRB）的启动子置换驱动类费城染色体急性淋巴细胞白血病。
NPJ Precis Oncol. 2023 Dec 9;7(1):132. doi: 10.1038/s41698-023-00485-7.
3
Frequent detection of genetic aberrations reveals novel pathogenesis and treatment modalities in systemic juvenile xanthogranuloma.频繁检测到的基因畸变揭示了系统性幼年性黄色肉芽肿的新发病机制和治疗方式。
Pediatr Investig. 2023 Aug 28;7(3):212-215. doi: 10.1002/ped4.12398. eCollection 2023 Sep.
4
Neuroimaging of pediatric tumors of the sellar region-A review in light of the 2021 WHO classification of tumors of the central nervous system.蝶鞍区小儿肿瘤的神经影像学——基于2021年世界卫生组织中枢神经系统肿瘤分类的综述
Front Pediatr. 2023 Jun 21;11:1162654. doi: 10.3389/fped.2023.1162654. eCollection 2023.
5
Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors.朗格汉斯细胞组织细胞增生症和组织细胞疾病的治疗：聚焦于 MAPK 通路抑制剂。
Paediatr Drugs. 2023 Jul;25(4):399-409. doi: 10.1007/s40272-023-00569-8. Epub 2023 May 19.
6
Disseminated Juvenile Xanthogranuloma with a Novel MYH9-FLT3 Fusion Presenting as a Blueberry Muffin Rash in a Neonate.散发型幼年性黄色肉芽肿伴新型MYH9-FLT3融合基因，表现为新生儿蓝莓松饼样皮疹
AJP Rep. 2023 Feb 17;13(1):e5-e10. doi: 10.1055/a-2015-1080. eCollection 2023 Jan.
本文引用的文献
1
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms.在组织细胞肿瘤中 CSF1R 和其他受体酪氨酸激酶的激活突变。
Nat Med. 2019 Dec;25(12):1839-1842. doi: 10.1038/s41591-019-0653-6. Epub 2019 Nov 25.
2
BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.中枢神经系统（CNS-JXG）幼年黄色肉芽肿家族性肿瘤中的 BRAF V600E 突变：包括小儿神经鞘黏液瘤病在内的修订诊断算法。
Acta Neuropathol Commun. 2019 Nov 4;7(1):168. doi: 10.1186/s40478-019-0811-6.
3
Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study.维莫非尼治疗儿童难治性多系统朗格汉斯细胞组织细胞增生症：一项国际观察性研究。
J Clin Oncol. 2019 Nov 1;37(31):2857-2865. doi: 10.1200/JCO.19.00456. Epub 2019 Sep 12.
4
-V600E-mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor.V600E 突变性 Rosai-Dorfman-Destombes 病和朗格汉斯细胞组织细胞增生症对 BRAF 抑制剂有反应。
Blood Adv. 2019 Jun 25;3(12):1848-1853. doi: 10.1182/bloodadvances.2019000093.
5
Clinical responses and persistent V600E blood cells in children with LCH treated with MAPK pathway inhibition.采用丝裂原活化蛋白激酶（MAPK）信号通路抑制治疗的朗格汉斯细胞组织细胞增多症（LCH）患儿的临床反应及持续性V600E血细胞
Blood. 2019 Apr 11;133(15):1691-1694. doi: 10.1182/blood-2018-10-878363. Epub 2019 Feb 4.
6
Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome.采用全基因组、全外显子组和转录组三平台测序对癌症进行临床基因组分析。
Nat Commun. 2018 Sep 27;9(1):3962. doi: 10.1038/s41467-018-06485-7.
7
V600E mutation detected in a case of Rosai-Dorfman disease.在一例Rosai-Dorfman病患者中检测到V600E突变。
Haematologica. 2018 Aug;103(8):e377-e379. doi: 10.3324/haematol.2018.190934. Epub 2018 May 10.
8
Molecular characterization of the histiocytoses: Neoplasia of dendritic cells and macrophages.组织细胞增多症的分子特征：树突状细胞和巨噬细胞的肿瘤性疾病。
Semin Cell Dev Biol. 2019 Feb;86:62-76. doi: 10.1016/j.semcdb.2018.03.002. Epub 2018 Mar 16.
9
Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study).针对54例 Erdheim-Chester病患者的靶向治疗，包括中断治疗后的随访（LOVE研究）。
Blood. 2017 Sep 14;130(11):1377-1380. doi: 10.1182/blood-2017-03-771873. Epub 2017 Jun 30.
10
Cyclin D1 Is Expressed in Neoplastic Cells of Langerhans Cell Histiocytosis but Not Reactive Langerhans Cell Proliferations.细胞周期蛋白D1在朗格汉斯细胞组织细胞增生症的肿瘤细胞中表达，但在反应性朗格汉斯细胞增殖中不表达。
Am J Surg Pathol. 2017 Oct;41(10):1390-1396. doi: 10.1097/PAS.0000000000000897.
Zotero 插件